Moe H. Kyaw

机构：Pfizer (United States), Pfizer (United Kingdom) · ORCID：0000-0002-7633-271X

发表论文 89 篇 · 总被引 2114 次 · h-index 27

代表论文

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study (2023 · Diabetes & Metabolism · 被引 27)
Epidemiology and clinical features of SARS-CoV-2 infection in children and adolescents in the pre-Omicron era: A global systematic review and meta-analysis (2024 · Journal of Global Health · 被引 13)
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines (2023 · Human Vaccines & Immunotherapeutics · 被引 12)
Duration of SARS-CoV-2 shedding: A systematic review (2024 · Journal of Global Health · 被引 10)
Incidence and outcome of SARS-CoV-2 reinfection in the pre-Omicron era: A global systematic review and meta-analysis (2023 · Journal of Global Health · 被引 9)
Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand (2023 · Expert Review of Vaccines · 被引 7)